CJC-1295 (No DAC) – 2mg

 Buy CJC-1295 (No DAC) 2mg

CJC-1295 (no DAC) is also known as Modified GRF 1-29 or Mod GRF (1-29). It is a synthetic peptide analog of the first 29 amino acids of natural growth hormone‑releasing hormone. GHRH is also called GRF in research literature. This peptide includes specific amino acid substitutions that improve stability and reduce enzymatic breakdown. These modifications also increase binding to GHRH receptors in laboratory models and help resist DPP‑IV cleavage and oxidation. CJC-1295 (no DAC) is supplied as a high‑purity lyophilized powder, typically showing purity of 99% or higher through HPLC testing. It is commonly available in 2 mg or 5 mg research vials. Researchers use this compound to study pulsatile growth hormone secretion and analyze pituitary signaling and IGF‑1 axis activity. The peptide is intended only for in vitro and in vivo laboratory research and is not approved for human consumption or therapeutic use.

CJC-1295 (No DAC) Mechanism of Action

In preclinical studies, CJC-1295 (no DAC) behaves as a selective GHRH receptor agonist. It binds to receptors on pituitary somatotroph cells and activates Gs‑protein signaling pathways. This interaction increases intracellular cAMP levels and activates protein kinase A, triggering pulsatile release of endogenous growth hormone. The peptide has a short half‑life of about 30 minutes, producing brief and controlled GH pulses that closely mimic natural hypothalamic and pituitary regulation. Unlike DAC variants, it does not cause sustained GH elevation. Cell and animal studies demonstrate increased GH pulse amplitude and IGF‑1 upregulation without receptor desensitization during short exposure.

CJC-1295 (No DAC) Peptide Sequence and Molecular Properties

CJC-1295 (No DAC), also known as Modified GRF (1-29), is a synthetic linear peptide containing 29 amino acids. It features four amino acid substitutions and C-terminal amidation, which are associated with improved resistance to certain degradation pathways.

CJC-1295 (No DAC) Molecular Specifications

Key Amino Acid Substitutions

These structural modifications distinguish CJC-1295 (No DAC) from natural GHRH(1-29). They are relevant to research on peptide stability, receptor signaling, and structure-activity relationships.

CJC-1295 (No DAC) 2 mg and 5 mg

CJC-1295 (no DAC) is available in standard research vial sizes. The 2 mg vial is suitable for small‑scale experiments including cell culture assays and early dose testing, allowing precise concentration control after reconstitution. The 5 mg vial is designed for larger or repeated studies such as long‑term animal models, GH pulse analysis, and IGF‑1 kinetics research. Larger vials also provide improved cost efficiency for extended research work. Both sizes are supplied as white lyophilized powder and require reconstitution using sterile or bacteriostatic water under sterile laboratory conditions.

CJC-1295 (No DAC) Research

Researchers widely use CJC-1295 (no DAC) in preclinical studies involving cell‑based assays and rodent models focused on pulsatile GH secretion. Studies show dose‑dependent increases in GH release along with elevated IGF‑1 levels while maintaining natural GH pulsatility. The peptide supports investigation of endocrine signaling, receptor interactions, and metabolic pathways such as lipolysis and protein synthesis. Research models often examine muscle repair mechanisms and adipose tissue metabolism. Compared with DAC versions, the no‑DAC variant allows improved control over hormone pulse timing, making it useful for studying natural GH rhythms. The compound remains investigational and is not approved for human use.

How to Store and Handle It?

Store unopened vials in a cool, dark, and dry environment. Long‑term storage is recommended at −20°C, while sealed vials may remain stable at 2–8°C for several months. Protect the peptide from light and moisture and avoid temperature fluctuations during storage. After reconstitution, refrigerate the solution at 2–8°C. Use reconstituted solutions within four to six weeks and avoid repeated freeze‑thaw cycles. Always follow sterile handling procedures and use proper PPE to prevent contamination.

Disclaimer

CJC-1295 (no DAC) is an investigational research peptide intended solely for in vitro laboratory research and in vivo animal studies. It is not approved by the FDA, EMA, or any regulatory authority for human use, diagnosis, treatment, or supplementation. The compound is classified as a non‑approved substance and is prohibited in athletic contexts. Preclinical findings do not predict human outcomes, and no claims are made regarding safety or efficacy in humans. Compounds should be handled only in qualified research facilities with institutional oversight and are strictly sold for laboratory research use only.

Referenced Citations

1. Teichman SL, et al. (2006). Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805.

• PubMed
• DOI: 10.1210/jc.2005-1536

2. Ionescu M, Frohman LA. (2006). Pulsatile Secretion of Growth Hormone (GH) Persists During Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797.

• PubMed
• DOI: 10.1210/jc.2006-1702

3. Alba M, et al. (2006). Once-Daily Administration of CJC-1295, a Long-Acting Growth Hormone-Releasing Hormone (GHRH) Analog, Normalizes Growth in the GHRH Knockout Mouse. American Journal of Physiology – Endocrinology and Metabolism, 291(6), E1290–E1294.

• PubMed
• Full research paper
• DOI: 10.1152/ajpendo.00201.2006